Sign in

REVB on Nasdaq

REVELATION BIOSCIENCES, INC.

REVELATION BIOSCIENCES, INC. is a clinical-stage life science company.2 It is headquartered in San Diego, United States.2 Its shares trade on Nasdaq under the symbol REVB.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerREVB on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address4660 Lajolla Village Drive, Suite 100, San Diego, Ca 921223
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300UKS15BEXENY6152
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O HARVARD BUSINESS SERVICES, INC., 19958 Lewes, United States2
  • Registered withDivision of Corporations, Department of State, 77138942

See how the biggest companies compare on our leaderboards

Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (“AKI”) and GEM-CKD as a treatment for chronic kidney disease (“CKD”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678-$9.1M in 2025−24% since 2021
-$15.0M-$10.0M-$5.0M02021: -$12.0M-$12.0M20212022: -$10.9M-$10.9M2022−9%2023: -$8.7M-$8.7M2023−20%2024: -$8.0M-$8.0M2024−8%2025: -$9.1M-$9.1M2025+14%
Net income9105678-$8.9M in 2025+244915% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$3.6K-$3.6K20192020: -$1.6M-$1.6M2020+44719%2021: -$12.0M-$12.0M2021+635%2022: -$10.8M-$10.8M2022−10%2023: -$120.3K-$120.3K2023−99%2024: -$15.0M-$15.0M2024+12406%2025: -$8.9M-$8.9M2025−41%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$4.1M$3.5M
General and administrative$5.0M$4.4M
Total operating expenses$9.1M$8.0M
Loss from operations-$9.1M-$8.0M
Change in fair value of warrant liability$2.2K$81.4K
Other income (expense), net$155.0K-$7.1M
Total other income (expense), net$157.2K-$7.1M
Net loss-$8.9M-$15.0M
Deemed dividends-$6.0M
Net loss attributable to common stockholders-$14.9M-$15.0M
Net loss per share, basic-$23.95-$1,052.16
Net loss per share, diluted-$23.95-$1,052.16
Weighted-average shares used to compute net loss per share, basic620.8K shares14.3K shares
Weighted-average shares used to compute net loss per share, diluted620.8K shares14.3K shares

Compare REVELATION BIOSCIENCES, INC. with another company

Corporate structure

REVELATION BIOSCIENCES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of REVELATION BIOSCIENCES, INC.

  • REVELATION BIOSCIENCES, INC. San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What REVELATION BIOSCIENCES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$117.1K8 Dec 31, 2025$151.1K8 Dec 31, 2024−22.5%
Property and equipment, before depreciation$117.1K8 Dec 31, 2025$151.1K8 Dec 31, 2024−22.5%
Accumulated depreciation$99.0K8 Dec 31, 2025$94.8K8 Dec 31, 2024+4.4%
Property and equipment, net$18.1K8 Dec 31, 2025$56.3K8 Dec 31, 2024−67.9%
Operating-lease assets (leased space)$722.3K8 Dec 31, 2025$08 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.7M8 Dec 31, 2025$6.5M8 Dec 31, 2024+64.6%

Properties, in its own words

Our corporate headquarters is located at 4660 La Jolla Village Dr., Suite 100, San Diego, California, where we currently have access to office space on an as-needed basis. We lease laboratory and office space at 5555 Oberlin Drive, Suite 100, San Diego, California, which consists of approximately 5,381 square feet. The lease expires on November 30, 2028. We believe that our current space is adequate for our needs.

Item 2 of the 10-K filed Feb 26, 2026.4

Leadership

Who has led REVELATION BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andreas Typaldos2020
  2. Sean H. Fitzpatrick2020
  3. James Rolke2022–now

Chief financial officer

  1. Sean H. Fitzpatrick2020
  2. Chester Stanley Zygmont Iii.2022–now
2025
Board members and other officers (13)

Former names

  • Petra Acquisition Inc.May 14, 2020 to Jan 11, 20223

Timeline

  1. Aug 19, 20268-K Executive or director change29
  2. Aug 6, 20268-K Results of operations30
  3. Jul 13, 20268-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed31
  4. Jun 24, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote32
  5. Jun 1, 20268-K Other events33
  6. May 7, 20268-K Results of operations34
  7. Mar 19, 20268-K Change to shareholders' rights; Shareholder vote35
  8. Feb 26, 20268-K Results of operations36
  9. Jan 29, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights37
  10. Jan 22, 20268-K Other events38
  11. Dec 3, 20258-K Change to shareholders' rights; Shareholder vote; Other events39
  12. Nov 6, 20258-K Results of operations40
  13. Jan 20, 2022New chief executive James Rolke becomes CEO14
  14. Dec 31, 2020New chief executive Sean H. Fitzpatrick becomes CEO16
  15. Oct 21, 2020New chief executive Andreas Typaldos becomes CEO15
  16. Nov 20, 2019Founded REVELATION BIOSCIENCES, INC. is founded2

Calendar

Coming up

  1. Oct 20, 2026Split Reverse split 1:7.41
  2. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($7.08) a share, on Nov 6, 2025.42

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results30
  2. May 7, 2026Reported quarterly or annual results34
  3. Feb 26, 2026Reported quarterly or annual results36
  4. Nov 6, 2025Reported quarterly or annual results40
  5. Aug 8, 2025Reported quarterly or annual results43
  6. May 8, 2025Reported quarterly or annual results44
  7. Mar 6, 2025Reported quarterly or annual results45
  8. Nov 8, 2024Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

327 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 89 major events, 54 insider forms, 27 large holders, 134 other. The latest 20:

  1. Aug 19, 20268-K EDGAR
  2. Aug 18, 20264 EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 18, 20264 EDGAR
  5. Aug 18, 20264 EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Aug 6, 202610-Q EDGAR
  10. Jul 13, 20268-A12B EDGAR
  11. Jul 13, 20268-K EDGAR
  12. Jun 24, 20268-K EDGAR
  13. Jun 1, 20268-K EDGAR
  14. May 15, 2026SCHEDULE 13G EDGAR
  15. May 11, 2026ARS EDGAR
  16. May 11, 2026DEF 14A EDGAR
  17. May 7, 20268-K EDGAR
  18. May 7, 202610-Q EDGAR
  19. May 1, 20264 EDGAR
  20. May 1, 20264 EDGAR

The 327 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 9 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 8, 2023TIDMARSH GEORGE FDirectorSale27,771$0.52$14.4KForm 4
Oct 16, 2023TIDMARSH GEORGE FDirectorSale1,845$0.65$1.2KForm 4
Oct 16, 2023TIDMARSH GEORGE FDirectorSale10,957$0.66$7.2KForm 4
Sep 28, 2023TIDMARSH GEORGE FDirectorSale1,429$0.69$986Form 4
Sep 18, 2023TIDMARSH GEORGE FDirectorSale4,000$0.74$3.0KForm 4
Sep 15, 2023TIDMARSH GEORGE FDirectorSale9,500$0.73$6.9KForm 4
Sep 14, 2023TIDMARSH GEORGE FDirectorSale12,000$0.75$9.0KForm 4
Apr 18, 2023TIDMARSH GEORGE FDirectorBuy25,000$1.16$29.0KForm 4
Apr 17, 2023TIDMARSH GEORGE FDirectorBuy26,500$1.16$30.7KForm 4
Feb 25, 2022TIDMARSH GEORGE FDirectorBuy20,000$1.60$32.0KForm 4
Feb 9, 2022TIDMARSH GEORGE FDirectorBuy30,000$2.55$76.5KForm 4
Feb 8, 2022TIDMARSH GEORGE FDirectorBuy1,000$2.54$2.5KForm 4
Feb 7, 2022TIDMARSH GEORGE FDirectorBuy42,100$2.61$109.9KForm 4
Feb 7, 2022TIDMARSH GEORGE FDirectorBuy42,100$2.61$109.9KForm 4
Feb 4, 2022TIDMARSH GEORGE FDirectorBuy9,900$2.34$23.1KForm 4
Feb 4, 2022TIDMARSH GEORGE FDirectorBuy7,900$2.31$18.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025James Rolke57$589.0K$1.5M61
2025Chester S. ZygmontIII45$425.2K$1.2M61
2024ChairmanDirector, and CEO$561.0K$813.2K61
2024CFO$405.0K$564.0K61

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sabby Management, LLC210,582$216.9K1.8%+111,150
Citadel Advisors LLC38,579$39.7K0.0%New
Geode Capital Management, LLC17,192$17.7K0.0%−26,003
Vanguard Fiduciary Trust Co13,127$13.5K0.0%No change
Tower Research Capital LLC (TRC)6,528$6.7K0.0%+2,454
Royal Bank Of Canada747$1.0K0.0%No change
SBI Securities Co., Ltd.344$3540.0%No change
Barclays PLC168$1730.0%New
Hrt Financial LP16,978$170.0%New
BNP PARIBAS ASSET MANAGEMENT Holding S.A.9$90.0%No change
Caitong International Asset Management Co., Ltd1$10.0%No change
Fmr LLC0$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How REVELATION BIOSCIENCES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARREVELATION BIOSCIENCES, INC.1
  • CIK0001810560
  • Employer ID (EIN)84-38984664
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4660 Lajolla Village Drive, Suite 100, San Diego, CA 921221
  • Phone650-800-37171
  • Shares outstanding3,983,416 as of Aug 3, 202612
  • Public float$3.4M as of Jun 30, 20254
  • AuditorBaker Tilly US, LLP, San Diego, CA PCAOB ID 23; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 14, 20201
  • Filings387 in all: 8-K (96), 4 (51), CORRESP (26), 10-Q (18), 3 (17), UPLOAD (16), SC 13G/A (15), EFFECT (14)1
    All 41 form types

    SC 13G (14), S-1/A (13), 424B3 (11), DEF 14A (11), PRE 14A (11), S-1 (8), DEFA14A (7), 10-K (6), 425 (5), S-3 (5), S-8 (5), SCHEDULE 13G/A (4), 8-K/A (3), NT 10-Q (3), S-4/A (3), SCHEDULE 13G (3), 10-K/A (2), 10-Q/A (2), 8-A12B (2), DRS (2), S-3/A (2), 144 (1), 25-NSE (1), 4/A (1), 424B4 (1), 5 (1), ARS (1), CERT (1), DEFR14A (1), NT 10-K (1), S-1MEF (1), S-4 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) May 11, 2026
    Latest 8-K (8-K) Aug 19, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.001 per shareREVBNasdaq

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks REVELATION BIOSCIENCES, INC. names in Item 1A of its 10-K filed Feb 26, 2026: 64 risks under these headings, as written.4

  • Risks Related to Our Business
  • Although our financial statements have been prepared on a going concern basis, we have a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we anticipate that we will continue to incur significant losses for the foreseeable future, and even if we were to generate revenue, we may never achieve or maintain profitability.
  • Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events affecting the financial services industry, could adversely affect our business, financial condition, results of operations or liquidity, either directly or through adverse impacts on certain of the third parties on which we rely to conduct certain aspects of our preclinical studies or clinical trials.
  • Risks Related to the Product Development, Regulatory Approval, Manufacturing andCommercialization of Our Product Candidates
  • If preclinical studies or clinical studies for our Product Candidates are unsuccessful or delayed, we will be unable to meet our future development goals.
  • Drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical studies are not necessarily predictive of our future results. Our clinical studies may fail to adequately demonstrate the safety and efficacy of our Product Candidates or any future product candidates.
  • The Clinical Studies of our Product Candidates’ have been and are planned to be conducted outside the United States, and the FDA or comparable foreign regulatory authorities may modify their regulatory pathway or conditions previously agreed upon, or may not accept data from such studies.
  • As an organization, we have never conducted pivotal clinical studies, and we may be unable to do so for any product candidates we may develop.
  • We may find it difficult to enroll patients in our clinical studies, which could delay or prevent us from proceeding with clinical studies.
  • Our Product Candidates and the administration of our Product Candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
  • Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if we complete the necessary clinical studies, we cannot predict when, or if, we will obtain regulatory approval to commercialize any of our Product Candidates, and the approval may be for a more narrow indication than we seek or be subject to other limitations or restrictions that limit its commercial profile.
The other 53 risks
  • Significant reductions in FDA staffing and changes in federal regulatory policy may delay or adversely affect the approval and commercialization of our Product Candidates.
  • Our business depends on the success of our Product Candidates, including obtaining regulatory approval to market our Product Candidates in the United States and/or other major foreign markets such as the EU.
  • Disruptions at the FDA and other national and foreign government authorities caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • Even if we obtain regulatory approval for a product candidate, our products and business will remain subject to ongoing regulatory obligations and review.
  • If one or more of our Product Candidates is approved for marketing in the United States or other countries, we may be subject, directly or indirectly, to United States or other countries equivalent federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Legislative or regulatory healthcare reforms in the United States or other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of our Product Candidates and to produce, market and distribute our Product Candidates after clearance or approval is obtained.
  • We face intense competition in an environment of rapid technological change and the possibility that our competitors may develop products and drug delivery systems that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our Product Candidates.
  • Changes in U.S. and international trade policies may adversely impact our business and operating results.
  • Artificial intelligence is playing an increasingly important role in biotechnology which may have an effect on us.
  • Risks Related to our Reliance on Third Parties
  • We rely on third parties to conduct certain elements of our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our Product Candidates.
  • We rely on third parties to manufacture the raw materials, including the active pharmaceutical ingredients that we use to create our therapeutic product candidate, and to manufacture the diagnostic devices, including the antibodies used for testing. Our business could be harmed if existing and prospective third parties fail to provide us with sufficient quantities of these materials and products or fail to do so at acceptable quality levels or prices.
  • We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our Product Candidates.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain effective patent rights for our Product Candidates or any future product candidates, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may not have sufficient patent lifespan to effectively protect our products and business.
  • If we are unable to maintain effective proprietary rights for our Product Candidates or any future product candidates, we may not be able to compete effectively in our markets.
  • We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful.
  • We may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development efforts.
  • Changes in United States and international patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Our inability to protect our trade secrets would harm our business and competitive position.
  • Intellectual property rights do not necessarily address all potential threats.
  • If our trademarks and trade names are not maintained and adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be adversely affected.
  • Risks Related to Our Business Operations
  • Our future success depends in part on our ability to retain our senior management team, directors and other key employees and to attract, retain and motivate other qualified personnel.
  • We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
  • We may not be successful in our efforts to identify, discover or license additional product candidates.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Ongoing healthcare legislative and regulatory reform measures may adversely affect our business, results of operations and financial condition.
  • Risks Related to Commercialization of Our Product Candidates
  • As we evolve from a company that is primarily involved in clinical development to a company that is also involved in commercialization, we may encounter difficulties in expanding our operations successfully.
  • We may seek to establish commercial collaborations for our Product Candidates and future product candidates, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development plans.
  • We currently have no Product Candidates approved for marketing. We do not have a marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our Product Candidates, we may be unable to generate any product revenue.
  • It may be difficult for us to profitably sell our Product Candidates, if and when approved, if coverage and reimbursement for these Product Candidates are limited by government authorities and/or third-party payor policies.
  • Our business entails a significant risk of clinical study and/or product liability and our ability to obtain sufficient insurance coverage could have a material effect on our business, financial condition, results of operations or prospects.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Our employees, contractors, vendors, principal investigators, consultants and future partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
  • Our business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers are subject to broadly applicable healthcare regulatory laws, which could expose us to penalties.
  • Data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information.
  • Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • Changes in our effective income tax rate could adversely affect our results of operations.
  • Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
  • We face the risk of product liability claims and may not be able to obtain insurance.
  • Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
  • We have no current plans to pay dividends on our shares of common stock.
  • Loss of Emerging Grown Company Status
  • Our common stock price may be volatile and as a result you could lose all or part of your investment.
  • Potential future sales pursuant to registration rights granted by the Company and under Rule 144 may depress the market price for our shares of common stock.
  • FINRA has adopted sales practice requirements, which may also limit a stockholder’s ability to buy and sell our common stock.
  • We face risks related to compliance with corporate governance laws and financial reporting standards.
  • Anti-takeover provisions contained in our Charter and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
  • Our Charter provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • If Revelation is not able to comply with the applicable continued listing requirements or standards of Nasdaq, Nasdaq could delist our common stock.
  • Revelation will continue to incur significant increased expenses and administrative burdens as a public company, which could negatively impact its business, financial condition and results of operations.
  • Revelation’s business and operations could be negatively affected if it becomes subject to any securities litigation or stockholder activism, which could cause Revelation to incur significant expense, hinder execution of business and growth strategy and impact its stock price.
  • Our common stock warrants may be accounted for as warrant liabilities and the changes in value of our warrants could have a material effect on our financial results.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61